Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats

Chemotherapy

Volumn 54, Issue 6, 2008, Pages 485-491

  Nakamura, Yoichi ^a   Satake, Kurika ^b   Sano, Kazumi ^b   Ito, Akiko ^b   Yoshikawa, Megumi ^b   Ikegami, Yoji ^b   Yoshida, Hisahiro ^b   Nakano, Hirofumi ^a   Oka, Mikio ^c   Sawada, Seigo ^d   Soda, Hiroshi ^e   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^e Sasebo Shiritsu Sogo Hospital   (Japan)

Author keywords

ABCG2 BCRP; EGFR inhibitor; Oral chemotherapy; Topoisomerase I inhibitor

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; GEFITINIB; GLUCURONIDE; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG POTENTIATION; DRUG TISSUE LEVEL; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; BILIARY TRACT; CAMPTOTHECIN; MALE; QUINAZOLINES; RATS; RATS, WISTAR;

EID: 52849098688     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000159625     Document Type: Article

References (26)

1. DeMario MD, Ratain MJ: Oral chemotherapy: rationale and future directions. J Clin Oncol 1998;16:2557-2567.
2. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115.
3. Sadahiro S, Suzuki T, Maeda Y, Ishikawa K, Tanaka Y, Yasuda S, Kamijo A, Makuuchi H, Murayama C: Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer. Chemotherapy 2007;53:442-445.
4. Hellriegel ET, Bjornsson TD, Hauck WW: Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 1996;60:601-607.
5. Kruijtzer CM, Beijnen JH, Schellens JH: Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 2002;7:516-530.
6. Kuppens IE, Breedveld P, Beijnen JH, JH Schellens: Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest 2005;23:443-464.
7. Foxwell BM, Mackie A, Ling V, Ryffel B: Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 1989;36:543-546.
8. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, ten Bokkel Huinink WW, Swart M, Lieverst J, Schellens JH: The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. Anticancer Drugs 2001;12:351-358.
9. Kruijtzer CM, Schellens JH, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, Rosing H, Mathot RA, Marcus S, van Tinteren H, Baas P: Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4508-4516.
10. Kruijtzer CM, Boot H, Beijnen JH, Lochs HL, Parnis FX, Planting AS, Pelgrims JM, Williams R, Mathot RA, Rosing H, Schot ME, Van Tinteren H, Schellens JH: Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann Oncol 2003;14:197-204.
11. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ 3 rd , Gilbertson R, Germain GS, Harwood FC, Houghton PJ: Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 2004;64:7491-7499.
12. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S: Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005;65:1541-1546.
13. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, Takemura M, Yabuuchi H, Soda H, Kohno S: Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 2005;49:337-343.
14. Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ, Stewart CF: Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 2006;66:4802-4807.
15. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T, Bates SE: Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999;59:5938-5946.
16. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, Shiozawa K, Kawabata S, Soda H, Ishikawa T, Tanabe S, Kohno S: Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 2001;288:827-832.
17. Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, Tamura T, Saijo N, Nishio K: Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ('Iressa') and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004;108:464-472.
18. Sano K, Yoshikawa M, Hayasaka S, Satake K, Ikegami Y, Yoshida H, Ishikawa T, Sawada S, Tanabe S: Simple non-ion-paired high-performance liquid chromatographic method for simultaneous quantitation of carboxylate and lactone forms of 14 new camptothecin derivatives. J Chromatogr B Analyt Technol Biomed Life Sci 2003;795:25-34.
19. Kaneda N, Hosokawa Y, Yokokura T: Simultaneous determination of the lactone and carboxylate forms of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in rat plasma by high performance liquid chromatography. Biol Pharm Bull 1997;20:815-819.
20. Kars MD, I?eri OD, Gunduz U, Molnar J: Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines. Chemotherapy 2008;54:194-200.
21. van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res 1998;4:2293-2297.
22. van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH: Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 1997;76:1181-1183.
23. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, van Tellingen O: Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 2000;6:4416-4421.
24. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A: Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993;84:697-702.
25. Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A: Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002;20:3122-3129.
26. Fujita K, Ando Y, Narabayashi M, Miya T, Nagashima F, Yamamoto W, Kodama K, Araki K, Endo H, Sasaki Y: Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyl oxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin from irinotecan. Drug Metab Dispos 2005;33:1785-1790.